Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 12/20 | 0.55 |
| ▸ | PRKCI | P41743 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12577791 | 0.91 | HTR7 (0.51) | HTR7FFAR1PRKCICNR2MAP2K4 | |
| SCHEMBL3451644 | 0.89 | PRKCI (0.49) | HTR7FFAR1PRKCICNR2MAP2K4 | |
| SCHEMBL205233 | 0.87 | CNR2 (0.48) | HTR7FFAR1PRKCICNR2MAP2K4 | |
| SCHEMBL20530676 | 0.86 | HTR7 (0.46) | HTR7FFAR1PRKCICNR2MAP2K4 | |
| SCHEMBL30466811 | 0.86 | HTR7 (0.46) | HTR7FFAR1PRKCICNR2MAP2K4 | |
| SCHEMBL1746865 | 0.86 | FFAR1 (0.48) | HTR7FFAR1PRKCICNR2 | |
| SCHEMBL1747360 | 0.84 | HTR7 (0.48) | HTR7FFAR1PRKCICNR2MAP2K4 | |
| SCHEMBL1747345 | 0.82 | HTR7 (0.43) | HTR7FFAR1PRKCICNR2MAP2K4 | |
| SCHEMBL14643102 | 0.82 | HTR7 (0.61) | HTR7FFAR1 | |
| SCHEMBL12640964 | 0.81 | CYP11B1 (0.43) | HTR7FFAR1PRKCICNR2MAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108059607-B | Sulfonylacetic acid or sulfonyl acetic acid derivative, and pharmaceutical composition, preparation method and application thereof | 中国科学院上海药物研究所 | 2020-11-17 | — | — | CN | disclosed |
| CN-107176944-B | Thiophene carboxylic acid compound or derivative thereof, pharmaceutical composition, preparation method and application thereof | 中国科学院上海药物研究所 | 2020-05-01 | — | — | CN | disclosed |
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-9072758-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9040525-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2703393-A1 | CYCLIC AMIDE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20140057871-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-20090186909-A1 | Oxadiazolidinedione Compound | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090186909-A1 | Oxadiazolidinedione Compound | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-2011788-A1 | OXADIAZOLIDINEDIONE COMPOUND | Astellas Pharma Inc. (JP) | 2009-01-07 | — | — | EP | disclosed |
| EP-2011788-A1 | OXADIAZOLIDINEDIONE COMPOUND | Astellas Pharma Inc. (JP) | 2009-01-07 | — | — | EP | disclosed |
| US-20080269220-A1 | Aminophenylpropanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| EP-1726580-A1 | AMINOPHENYLPROPANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2006-11-29 | — | — | EP | disclosed |
| US-20060258722-A1 | Condensed ring compound | TAKEDA PHARMACEUTICAL COMPANY., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| EP-1630152-A1 | CONDENSED RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2006-03-01 | — | — | EP | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR4A1 | HTR7 723/4885FFAR1 27/4885PRKCI 1751/4885 |
| US-20140057871-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR4A1 | HTR7 718/4885FFAR1 29/4885PRKCI 1862/4885 |
| US-20090186909-A1 | Oxadiazolidinedione Compound | GPR119, GPR39, GPR65 | HTR7 976/4885FFAR1 64/4885PRKCI 2686/4885 |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | HTR7 481/4885FFAR1 25/4885PRKCI 1205/4885 |
| US-20080269220-A1 | Aminophenylpropanoic Acid Derivative | GPR119, GPR55, GPR65 | HTR7 764/4885FFAR1 5/4885PRKCI 3518/4885 |
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | HTR7 453/4885FFAR1 33/4885PRKCI 3560/4885 |
| US-20060258722-A1 | Condensed ring compound | GPR119, GLP1R, GCGR | HTR7 549/4885FFAR1 93/4885PRKCI 4633/4885 |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | HTR7 586/4885FFAR1 26/4885PRKCI 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.